Urticaria and angioedema as possible reactions of omalizumab*
Lido
6248
Vezesque se leu este artigo
2604
Total PDF
3644
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 10 | 151 | 110 | 261 |
| 2025 9 | 116 | 59 | 175 |
| 2025 8 | 114 | 56 | 170 |
| 2025 7 | 144 | 63 | 207 |
| 2025 6 | 112 | 50 | 162 |
| 2025 5 | 161 | 51 | 212 |
| 2025 4 | 108 | 41 | 149 |
| 2025 3 | 121 | 50 | 171 |
| 2025 2 | 134 | 69 | 203 |
| 2025 1 | 74 | 45 | 119 |
| 2024 12 | 72 | 37 | 109 |
| 2024 11 | 88 | 49 | 137 |
| 2024 10 | 80 | 68 | 148 |
| 2024 9 | 111 | 73 | 184 |
| 2024 8 | 112 | 96 | 208 |
| 2024 7 | 97 | 100 | 197 |
| 2024 6 | 127 | 73 | 200 |
| 2024 5 | 74 | 58 | 132 |
| 2024 4 | 78 | 65 | 143 |
| 2024 3 | 76 | 68 | 144 |
| 2024 2 | 111 | 82 | 193 |
| 2024 1 | 76 | 38 | 114 |
| 2023 12 | 51 | 44 | 95 |
| 2023 11 | 47 | 51 | 98 |
| 2023 10 | 43 | 53 | 96 |
| 2023 9 | 46 | 36 | 82 |
| 2023 8 | 36 | 23 | 59 |
| 2023 7 | 37 | 20 | 57 |
| 2023 6 | 59 | 33 | 92 |
| 2023 5 | 40 | 13 | 53 |
| 2023 4 | 32 | 12 | 44 |
| 2023 3 | 24 | 28 | 52 |
| 2023 2 | 25 | 24 | 49 |
| 2023 1 | 33 | 22 | 55 |
| 2022 12 | 25 | 17 | 42 |
| 2022 11 | 37 | 44 | 81 |
| 2022 10 | 54 | 25 | 79 |
| 2022 9 | 27 | 36 | 63 |
| 2022 8 | 30 | 36 | 66 |
| 2022 7 | 27 | 37 | 64 |
| 2022 6 | 31 | 50 | 81 |
| 2022 5 | 23 | 42 | 65 |
| 2022 4 | 27 | 32 | 59 |
| 2022 3 | 26 | 44 | 70 |
| 2022 2 | 37 | 28 | 65 |
| 2021 1 | 69 | 56 | 125 |
| 2021 12 | 29 | 41 | 70 |
| 2021 11 | 29 | 32 | 61 |
| 2021 10 | 59 | 60 | 119 |
| 2021 9 | 31 | 26 | 57 |
| 2021 8 | 69 | 22 | 91 |
| 2021 7 | 67 | 23 | 90 |
| 2021 6 | 12 | 21 | 33 |
| 2021 5 | 25 | 36 | 61 |
| 2021 4 | 60 | 113 | 173 |
| 2021 3 | 10 | 9 | 19 |
| 2021 2 | 10 | 5 | 15 |
| 2020 1 | 9 | 2 | 11 |
| 2020 12 | 11 | 7 | 18 |
Mostrar tudo
